Apo A-I modulating therapies

Stephen Nicholls

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


The substantial residual risk of cardiovascular events despite the implementation of effective lowering of low-density lipoprotein cholesterol highlights the need to develop additional cardioprotective therapies. Evidence from population and animal studies suggests that high-density lipoproteins (HDLs), the protective lipid particles, may represent a target for therapeutic modification. As a result intensive efforts are in progress to develop new agents that promote HDL activity. Among these different approaches, a range of strategies that target apolipoprotein A-I, the major protein carried on HDL, are being evaluated.

Original languageEnglish
Pages (from-to)537-543
Number of pages7
JournalCurrent Cardiology Reports
Issue number6
Publication statusPublished or Issued - Dec 2011


  • Apolipoprotein A-I
  • Atherosclerosis
  • Coronary artery disease
  • High-density lipoproteins
  • Lipids
  • Risk factors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this